Fig. 5From: Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drugPharmacokinetics of CR6086 in rats. a Unbound concentrations of CR6086 administered orally in the dose range of 1–30 mg/kg. The dashed line represents the inhibition constant (36.2 ng/ml) value for the rat prostaglandin E2 receptor 4. b Pharmacokinetic parametersBack to article page